Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New coronavirus mRNA vaccine for targeted stimulation of humoral immunity and cellular immunity

A vaccine and virus technology, applied in the field of immunity, can solve problems such as immune escape

Active Publication Date: 2021-11-12
SHENZHEN BAY LAB +1
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, the current mRNA vaccines mainly have the following two problems: On the one hand, the two new coronavirus mRNA vaccines that have been successfully marketed at present tend to induce neutralizing antibodies to exert a protective immune response, and have not yet explored the targeted induction of T Cellular Immune Responses Develop Specific Design
On the other hand, some dominant variants produced by the continuous mutation of the new coronavirus during the epidemic include Alpha variant (B.1.1.7), Beta variant (B.1.351), Gamma variant (P.1), Delta variant (B. .1.617.2), etc., for antibodies induced by current mRNA vaccines, severe immune escape may occur

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New coronavirus mRNA vaccine for targeted stimulation of humoral immunity and cellular immunity
  • New coronavirus mRNA vaccine for targeted stimulation of humoral immunity and cellular immunity
  • New coronavirus mRNA vaccine for targeted stimulation of humoral immunity and cellular immunity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] This embodiment provides a combination of antigen expression vectors for a novel coronavirus mRNA vaccine. The combination of antigen expression vectors includes three antigen expression vectors, pCA-RBD-SA, pCA-Ub-rMN and pCA-Ub-NSPs, respectively.

[0069] These antigen expression vectors refer to Figures 1~3 , wherein, the pCA-RBD-SA plasmid has an antigen coding region, and the antigen coding region includes the sequence encoding the tPA signal peptide and the sequence encoding the RBD-SA fragment connected in sequence, and the sequence encoding the RBD-SA fragment 3' A sequence encoding a Flag tag and a stop codon were also inserted at the ends (Flag sequence and stop codon are not shown in the figure). The upstream and downstream of the antigen coding region are also connected with T7 promoter, 5'-end untranslated region (5'-UTR), 3'-end untranslated region (3'-UTR), and polyadenylation (polyA).

[0070] The pCA-Ub-rMN plasmid has an antigen coding region, and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a new coronavirus mRNA vaccine for targeted stimulation of humoral immunity and cellular immunity. The first aspect of the invention provides a separated DNA molecule combination, wherein the DNA molecule combination comprises a first DNA molecule and at least one of a second DNA molecule and a third DNA molecule. Through the combination of the first DNA molecule and the second DNA molecule and / or the third DNA molecule, mRNA finally synthesized by the first DNA molecule is used for inducing a high-titer cross neutralizing antibody, and mRNA finally synthesized by the second DNA molecule and / or the third DNA molecule is used for inducing new coronavirus-specific cytotoxic T lymphocytes, so that relatively independent humoral immune response and cellular immune response are efficiently activated at the same time, and breakthrough infection caused by mutant strains generated in the epidemic propagation process of new coronavirus is coped with.

Description

technical field [0001] The present application relates to the field of immunity technology, in particular to a novel coronavirus mRNA vaccine that targets and stimulates humoral immunity and cellular immunity. Background technique [0002] Compared with other traditional vaccines, mRNA vaccines have the advantages of short research and development cycle and relatively low research and development costs. At the same time, their physical and chemical properties such as solubility are suitable for drug research and development, with high safety; and they have low side effects, and there is no integration, induced gene mutation and foreign sources. Therefore, it has become a hot spot in vaccine research and development. In the design of the target antigen gene, according to the type of protective immune response to be induced, different antigen sequences are selected for construction. An ideal vaccine design can effectively induce pathogen-specific humoral and cellular immune re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/62C12N15/85A61K39/215A61K9/51A61P31/14
CPCC07K14/005C12N15/85A61K39/12A61K9/5107A61P31/14C12N2770/20022C07K2319/02C07K2319/95C07K2319/40C12N2800/107C12N2770/20034A61K2039/53
Inventor 程功太万博冯胜勇童良琴庞慕加蔡珠明
Owner SHENZHEN BAY LAB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com